Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Eisai Co., Ltd. revealed today that fully-fledged operations and organization activities haveactually started at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary justrecently developed in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia). Eisai Saudi Arabia is a wholly-owned subsidiary of Eisai’s European local headoffice, Eisai Europe Ltd. (Location: U.K.).
In the 1960s, Eisai began service in the Middle East marketing and selling Eisai items throughlocal circulation partners. In Saudi Arabia, Eisai started selling the peripheral neuropathy treatmentMethycobal® in 2009, and has because broadened the item pipeline with the launch of antiepileptic drug Fycompa® in 2018, anticancer drug Lenvima® in 2020, and others, through regional circulation partners.Eisai Saudi Arabia was developed in April 2024 in order to develop an internal sales system in Saudi Arabia, and is in the procedure of taking over industrial rights for the Eisai items in Saudi Arabia from regional circulation partners. Eisai Saudi Arabia began sales and marketing activities for Methycobaland Fycompa in October 2024, and prepares to broaden activities to consistof Lenvima and anticancer representative Halaven® from April2025 Moreover, an application for Alzheimer’s illness treatment lecanemab(generic name, worldwide brandname name: Leqembi®) hasactually been sent for evaluation in Saudi Arabia.
Saudi Arabia’s pharmaceutical market re